# Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

> **NCT00935012** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- ATTR-CM
- TTR-CM

## Interventions

- **DRUG:** tafamidis

## Key facts

- **NCT ID:** NCT00935012
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-30
- **Primary completion:** 2019-11-20
- **Final completion:** 2019-11-20
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00935012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00935012, "Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00935012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*